Janus Henderson Group plc's 13G Filing for Vistagen Therapeutics, Inc.

Janus Henderson Group plc filed a Schedule 13G with the SEC, disclosing its beneficial ownership of 13.6% of Vistagen Therapeutics, Inc.'s common stock, amounting to 4,165,767 shares. The filing indicates that Janus Henderson Group plc, along with its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, may be deemed the beneficial owners of these shares. The shares are held in the ordinary course of business and not for the purpose of influencing the control of Vistagen Therapeutics. The filing also includes a power of attorney granted to Kristin Mariani and Caroline Barotti for executing documents related to ownership or control-person reporting requirements.